Welcome to our dedicated page for Unity Btech news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Btech stock.
Unity Biotechnology, Inc. has focused on developing therapeutics intended to slow, halt or reverse diseases of aging, including medicines that selectively eliminate or modulate senescent cells in age-related ophthalmologic and neurologic diseases. Company news has centered on UBX1325 (foselutoclax), an intravitreal BCL-xL inhibitor studied for diabetic macular edema, and clinical updates from the ASPIRE and BEHOLD studies.
Recurring updates also cover presentations and publications of retinal-disease data, quarterly financial results, cash-burn reduction, strategic alternatives for UBX1325 and related Tie2/anti-VEGF and Tie2 agonistic antibody assets, and board or governance changes tied to the company's biotechnology pipeline.
UNITY Biotechnology (UBX) has secured an $80 million debt facility with Hercules Capital to enhance its financial flexibility for developing lead senolytic candidates, UBX0101 and UBX1325. At closing, Unity accessed $25 million from the facility, with an additional $30 million contingent on future milestones, and $25 million subject to Hercules' approval. CEO Anirvan Ghosh expressed confidence in the partnership with Hercules, emphasizing the support for innovative life sciences. Further details will be disclosed in a forthcoming Form 8-K report.
UNITY Biotechnology, Inc. (NASDAQ:UBX) reported its Q2 2020 financial results, showing cash reserves of $111.8 million as of June 30, down from $125.0 million at the end of 2019. The operating loss decreased to $23.3 million compared to $24.5 million a year earlier. R&D expenses dropped to $16.1 million, while G&A expenses increased to $6.3 million due to non-cash stock compensation. The company anticipates significant data readouts from its Phase 2 osteoarthritis study and the initiation of its ophthalmology program in the latter half of 2020. Current funds are projected to last until mid-2021.
UNITY Biotechnology, Inc. (NASDAQ:UBX) announced it will release its financial results for Q2 ending June 30, 2020, on July 31, 2020, after market close. The company is focused on developing therapeutics aimed at extending healthspan by targeting diseases of aging, specifically through senolytic medicines. These therapies aim to eliminate senescent cells, potentially benefiting age-related ailments such as osteoarthritis and neurological diseases. Notably, no conference call will accompany this financial update.
UNITY Biotechnology provided updates on its development programs, anticipating 12-week results for UBX0101 in osteoarthritis by Q3 2020. This Phase 2 study, involving 0.5 mg, 2.0 mg, and 4.0 mg dosages, targets patients with moderate-to-severe knee osteoarthritis. Additionally, the first-in-human study for UBX1325, aimed at age-related eye diseases, is expected to begin in 2H 2020. The company has secured exclusive rights for UBX1325 outside Greater China, and ongoing clinical trials are being affected by the COVID-19 pandemic.
UNITY Biotechnology announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 4:40 PM E.T. The event will be held virtually, and a live audio webcast will be available on the company's website, with an archived replay available for 90 days. UNITY focuses on developing therapeutics to extend healthspan by targeting cellular senescence, which contributes to age-related diseases. The company's senolytic medicines aim to eliminate senescent cells, potentially reversing conditions like osteoarthritis and age-related eye diseases.
UNITY Biotechnology (NASDAQ: UBX) announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference, scheduled for June 11, 2020, at 3:50 PM E.T. The event will be held virtually, and a live audio webcast will be available on UNITY's website, with an archived replay accessible for 90 days.
UNITY focuses on developing therapeutics to extend healthspan by targeting cellular senescence, a key driver of age-related diseases. Their senolytic medicines aim to eliminate senescent cells, potentially slowing or reversing conditions like osteoarthritis.
UNITY Biotechnology, Inc. (NASDAQ:UBX) reported its Q1 2020 financial results, revealing a cash balance of $109.2 million compared to $125.0 million at the end of Q4 2019. The operating loss increased to $27.2 million, up from $19.7 million year-over-year, driven by higher clinical study costs for UBX0101. Despite the challenges posed by the COVID-19 pandemic, UNITY completed enrollment for both Phase 1b and Phase 2 studies of UBX0101. Results are expected in the second half of 2020, while the company anticipates sufficient capital to fund operations into mid-2021.
UNITY Biotechnology (NASDAQ:UBX) plans to report its Q1 2020 financial results on May 7, 2020, after NASDAQ market close. No conference call will follow the announcement. The company focuses on developing therapeutics to extend healthspan by targeting cellular senescence, a key factor in aging and age-related diseases. UNITY aims to create senolytic medicines to eliminate senescent cells that contribute to chronic inflammation and other age-related health issues.